CNTA

NEUTRALM&A

Centessa Pharmaceuticals plc

2026-06-05

Price

$39.62

-0.45%

Score12.0Top Tier

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.5xvs 20d avg

Analysis

Centessa Pharmaceuticals (CNTA) is currently trading as a pure M&A arbitrage play following Eli Lilly's definitive agreement to acquire the company. The deal structure provides a $38.00 per share cash floor plus a Contingent Value Right (CVR) worth up to $9.00 per share, explaining why CNTA is trading at $39.62 as the market prices in the CVR's potential. Technical signals like QUIET_STORM and STEADY_CLIMB, alongside an exceptionally low realized volatility of 2.5%, perfectly reflect this post-acquisition-announcement price pegging. The current RISK_ON macro regime, highlighted by tight high-yield credit spreads at 0.74%, provides high conviction that financing and broader market conditions will not derail the transaction.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKBARGAIN HUNTER

Key Takeaways

Actionable Thesis: CNTA offers an asymmetric M&A arbitrage setup with a hard cash floor of $38.00 and embedded optionality via the $9.00 CVR currently priced at just ~$1.62 [2.1.4].
Key Risk: Regulatory hurdles or shareholder rejection at the upcoming June 12th vote could jeopardize the deal, though market pricing implies minimal deal-break risk.
What to Watch: Focus on the June 12th shareholder vote and any FDA updates regarding the CVR milestones tied to cleminorexton and ORX142 approvals.

← Back to 2026-06-05 View Full CNTA History →Yahoo Finance &nearr;